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Key Points
• Immunoproteasome in-
hibitor ONX-0914 has
antimyeloma activity
in vitro similar to that
of bortezomib and
carfilzomib.
• LU-102 sensitizes MM
cells to a pharmacolog-
ically relevant concen-
tration of ONX-0914,
which synergizes with
bortezomib in vivo.
Proteasome inhibitors bortezomib, carﬁlzomib and ixazomib (approved by the US Food
and Drug Administration [FDA]) induce remissions in patients withmultiplemyeloma (MM),
but most patients eventually become resistant. MM and other hematologic malignancies
express ubiquitous constitutive proteasomes and lymphoid tissue–speciﬁc immunoprotea-
somes; immunoproteasome expression is increased in resistant patients. Immunoprotea-
somes contain 3 distinct pairs of active sites, b5i, b1i, and b2i, which are different from
their constitutive b5c, b1c, and b2c counterparts. Bortezomib and carﬁlzomib block b5c
and b5i sites. We report here that pharmacologically relevant concentrations of b5i-speciﬁc
inhibitor ONX-0914 show cytotoxicity in MM cell lines similar to that of carﬁlzomib and
bortezomib. In addition, increasing immunoproteasome expression by interferon-g
increases sensitivity to ONX-0914 but not to carﬁlzomib. LU-102, an inhibitor of b2 sites,
dramatically sensitizes MM cell lines and primary cells to ONX-0914. ONX-0914
synergizes with all FDA-approved proteasome inhibitors in MM in vitro and in vivo.
Thus, immunoproteasome inhibitors, currently in clinical trials for the treatment of
autoimmune diseases, should also be considered for the treatment of MM.
Introduction
Multiple myeloma (MM) is a plasma cell malignancy with a median survival of approximately 7 years.1,2 The
proteasome inhibitors bortezomib, carfilzomib, and ixazomib are critical components of MM treatment
regimens. Although initial response rates with these treatments are high, the majority of patients eventually
become resistant and succumb to the disease, underlining a need for new treatments.
MM cells express constitutive proteasomes and immunoproteasomes. The constitutive protea-
somes are expressed ubiquitously through the body, whereas immunoproteasomes are highly
expressed in cells and tissues of the immune system3,4 and constitute 30% to 90% of the total
proteasomes in MM cells.5,6 A decrease in the expression of immunoproteasomes correlates with a
better response to bortezomib in patients,7 whereas patients with relapsed/refractory MM show
increased immunoproteasome activity.8 Thus, immunoproteasome inhibition may be the key to
increasing proteasome inhibition (and thereby enhancing MM cell death) in patients with relapsed/
refractory MM.
Both types of proteasomes have 3 pairs of active sites, the b5c (PSMB5, or chymotrypsin-like), b1c
(PSMB6, or caspase-like), and the b2c (PSMB7, or trypsin-like) sites in the constitutive proteasome and
the b5i (PSMB8, LMP7), b1i (PSMB9, LMP2), and the b2i (PSMB10, LMP10, MECL1) sites in the
immunoproteasome.9 Bortezomib, carfilzomib and ixazomib are potent inhibitors of the b5i and b5c
sites. Previous studies have shown that specific inhibition of b5i is not sufficient to kill myeloma cells6;
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however, it is not known whether coinhibition of b1i and b2i sites
will make an inhibitor cytotoxic. We developed LU-102, a specific
cell-permeable inhibitor of b2 sites and found that it dramatically
sensitizes myeloma and solid tumor cells to bortezomib and
carfilzomib,10,11 restores sensitivity of primary cells from bortezo-
mib- and carfilzomib-resistant myeloma patients to these agents,
and synergizes with carfilzomib in murine models of myeloma.12
Combined inhibition of b5 and b2 sites may increase mechanism-
based toxicity (eg, gastrointestinal, renal, and cardiac toxicities)
because of increased inhibition of protein breakdown in these
tissues; however, replacing bortezomib and carfilzomib with an
immunoproteasome inhibitor should reduce these adverse ef-
fects because expression of immunoproteasomes in these tissues
is low. Mice lacking all 3 immunoproteasomes subunits are
viable.13
Although several immunoproteasome inhibitors have been tested
against MM cells, their specificity at active doses was not
confirmed,5,14-17 and the effect of combined inhibition of b5i and
b2 sites has not been explored. b5i inhibitor ONX-0914 (PR-957)
has in vivo activity in murine models of many different autoimmune
disorders,18-22 in which selective killing of auto-antibody plasma cells
is believed to contribute to efficacy. A derivative of ONX-0914, KZR-
616, is currently being developed for the treatment of autoimmune
diseases. It recently completed a successful phase 1a study in
healthy volunteers (ACTRN12616001040459)23 and seems to
bypass the toxic effects (eg, gastrointestinal toxicities, neurotoxicity).
Therefore, the possibility of repositioning KZR-616 for the treatment
of MM must be explored.
KZR-616 is not yet available to us; therefore, we used ONX-0914
as a compound tool to determine of feasibility of inhibition
immunoproteasomes for the treatment of MM. Here, we demon-
strate that MM cells, which are sensitive to clinically relevant
concentrations of carfilzomib and bortezomib, also respond to
treatment with pharmacologically relevant concentrations of ONX-
0914. Furthermore, we demonstrate that subtoxic doses of the
b2 inhibitor LU-102 strongly sensitize MM cells to ONX-0914,
as observed previously for bortezomib and carfilzomib.11,12,24
We also found that ONX-0914 synergizes with inhibitors approved by
the US Food and Drug Administration (FDA) in vitro as well as
in vivo.
Materials and methods
Cell lines
KMS-11 cells were purchased from the Health Science Research
Resources Bank (Osaka, Japan). NCI-H929 and RPMI-8226 cells
were purchased from the American Type Culture Collection. All
other cells lines were authenticated by the University of Vermont
Human Cell Line Authentication Facility. Cells were cultured in
RPMI-1640 (Hyclone) medium supplemented with 10% fetal bovine
serum (Hyclone), penicillin (100 mg/mL), streptomycin (100 U/mL),
and the antimycoplasma antibiotic Plasmocin (1.5 mg/mL; InvivoGen,
San Diego, CA). Patient samples were collected in accordance with
the Declaration of Helsinki and under the protocol approved by the
Dartmouth College Committee on Protection of Human Subjects
or approved by the Dana-Farber Cancer Institute Committee on
Protection of Human Subjects, and all animal experiments were
conducted according to the protocol approved by Dartmouth
Institutional Animal Care and Use Committee.
Cell-based assays
Bortezomib, carfilzomib, and ixazomib were purchased from LC
Laboratories, and ONX-0914 was purchased from MedKoo.
LU-102 was synthesized as described.11 Unless otherwise stated,
cell lines were treated with carfilzomib, bortezomib, ONX-0914,
and ixazomib for 1 hour and then cultured in the presence or
absence of LU-102 for 47 hours; viability was then assessed
with Alamar Blue mitochondrial dye conversion assay (Invitrogen
or Bio-Rad) as described.25 For flow cytometry, CD138-PE
(BD Pharmingen #550805) and Zombie Aqua Fixable Viability
Kit (BioLegend #423101) were used. The values on all graphs
are averages 6 standard error of the mean of a number of
experiments (supplemental Table 1). At least 2 biological replicates
were averaged to define the 4-parameter fit of concentration-
dependence curves used to determine the half maximal inhibitory
concentration.
Cells were lysed with 0.05% digitonin in 50 mM tris(hydroxymethyl)
aminomethane (pH 7.5), 250 mM sucrose, 5 mM MgCl2, 1 mM
adenosine triphosphate, 0.5 mM EDTA, and 1 mM dithiothreitol. To
assay activity of b5i, b5c, b1i, and b1c subunits, 10 mg of protein
were coincubated with 2.5 mM BODIPY-NC-001 and BODIPY-
NC-005-VS (compounds 23 and 24 in Verdoes et al26) for 1 hour at
37°C. To resolve b2, b2i, b1, and b1i subunits, extracts were co-
treated with MV-15127 and BODIPY-NC-001.26 Proteasome sub-
units were separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis using 0.75-mm-thick 12.5% gels and a Laemmli
buffer system. Probe-modified subunits were revealed by fluorescent
imaging. Gels were then stained with Coomassie blue dye as a
loading control. b5i and b5c activity was determined using the
7-amino-4-methylcoumarin amide (amc) substrates Suc-LLVY-amc
(b5c 1 b5i, 100 mM) and Ac-ANW-amc (b5i, 200 mM)28 as
described.24,29
In vivo testing
Male NSG (Nod/Scid/IL-2 receptor g-chain knockout; The Jackson
Laboratory) mice were treated with 100 cgy of radiation (from
a cesium irradiator; sublethal dose) based on Mitsiades et al.30
The following day, 2 million MM1.S cells in phosphate-buffered
saline were injected into these mice via the tail vein. Bortezomib
(0.5 mg/kg) and ONX-0914 (up to 15 mg/kg) were dissolved in
10 mM calcium citrate (pH 6), with 10% Captisol and injected
subcutaneously 2 times per week (as indicated in Figure 4D).
Animals were euthanized when they began dragging a hind leg.
Blood samples were taken, and human immunoglobulin G l levels
were determined by western blot using anti-human l-chain antibody
(Vector, #AI-33070, 1:500), with a fluorescently labeled anti-goat
secondary antibody (Rockland, #605-745-002, 1:10000), and they
were imaged on an Odyssey (LICOR) scanner.
Results
ONX-0914 is cytotoxic to MM cells that express high
levels of b5i
To determine whether the immunoproteasome content in cultured
MM cells is similar to that of primary MM cells in which 30% to 90%
of proteasomes are immunoproteasomes,5 we treated extracts
with activity-based probes (ie, fluorescently labeled irreversible
inhibitors) BODIPY-NC-005-vs and BODIPY-NC-001,26 and
then resolved the fluorescently labeled subunits on an sodium
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Figure 1. Effect of ONX-0914 on MM cells. (A) Expression of immunoproteasomes in MM cell lines as determined by the activity-based probes. Immortalized B-cell line
LG2, which expresses high levels of immunoproteasomes, and HeLa cells, which express little or no immunoproteasomes were used as references (n 5 2). (B) Cleavage rates
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dodecyl sulfate-polyacrylamide gel electrophoresis gel (Figure 1A).
Most MM cells have almost equal amounts of active b5i and b5c
(MM1.S, U266, RPMI-8226) or have a greater amount of b5c
(H929, KMS-11, KMS-18, KMS-21-PE, LR5). Thus, cultured MM
cells express immunoproteasomes, although they have slightly
lower b5i:b5c ratios than the primary myeloma cells reported in the
literature5 or that we isolated from patients (Figure 1B).
We then pulse-treated a panel of 6 MM cells with ONX-0914 for 1
hour and determined their viability 48 hours later (Figure 1C). The
pulse treatment better mimics the bolus injections currently used in
patients than the continuous exposure used in most in vitro studies.25
In parallel experiments, we assessed the extent to which ONX-0914
inhibits the different active sites in MM1.S cells (Figure 1C). Although
b5i specific at low concentrations (eg, 100 nM), this agent inhibited
other subunits of immune and constitutive proteasomes at higher
concentrations. ONX-0914 (1 mM) inhibited proteasomes to the
same degree as it did in the tissues of treated mice at the maximum
tolerated dose.18 This represents complete inhibition of b5i and
;50% inhibition of b5c, b1i, and b1c (Figure 1C). Therefore, for the
remainder of the study, we considered 1 mM ONX-0914 to be a
pharmacologically relevant concentration. This concentration was
cytotoxic to several cell lines. We have previously reported that a
1-hour pulse with 100 nM bortezomib leads to a clinically achievable
75% inhibition of b5 subunits25 and that 33 nM carfilzomib causes
the clinically achievable ;90% b5 inhibition.24 As with ONX-0914,
bortezomib and carfilzomib reduced the viability of MM1.S, MM1.R,
and H929 cells, but not of any other cell lines at these clinically
relevant concentrations (Figure 1D). Thus, at relevant doses, ONX-
0914 has in vitro cytotoxicity similar to that of carfilzomib and
bortezomib.
Because primary cells have a higher b5i:b5c ratio (Figure 1B), we
tested whether increasing the expression of b5i by interferon-g
(IFN-g) specifically enhances sensitivity to an immunoproteasome
inhibitor. Indeed, IFN-g treatment increased cytotoxicity to ONX-
0914, but not to carfilzomib (Figure 1E), indicating that increased
expression of immunoproteasomes enhances sensitivity to immu-
noproteasome inhibitors.
Cells upregulate b5c as they recover from
b5i inhibition
With the exception of the few most sensitive MM cell lines, proteasome
activity in MM cells recovers after treatment with clinically relevant
concentrations of bortezomib.25 A 1-hour pulse treatment of RPMI-
8226 cells with subtoxic levels (1 mM) of ONX-0914 or with 100 nM
carfilzomib (Figure 2A) causes a similar recovery of total b5 activity
(eg, combined b5i and b5c activity) within 18 hours (Figure 2B-C).
This recovery is mediated by the transcription factor Nrf1,31,32 which
regulates the transcription of all constitutive proteasome subunits, but
Figure 1. (continued) of b5i-specific substrate Ac-ANW-amc and of b5c and b5i substrate Suc-LLVY-amc were measured in extracts of primary MM cells isolated from
relapsed/refractory patients using EasySep Human CD138 Positive Selection Kit II (STEMCELL Technologies, Catalog #18357), and ANW:LLVY ratio was used as readout of
relative b5i expression. (C) ONX-0914 is cytotoxic to MM cells. Top: cells were treated with ONX-0914 for 1 hour followed by Alamar Blue assay 47 hours later (n 5 2-3; see
supplemental Table 1 for exact number of cells for each cell line). In a parallel experiment, proteasome inhibition was measured by site-specific fluorogenic substrates (middle graph)
or activity-based probes (bottom graph) immediately after 1-hour treatment with ONX-0914 (n 5 4). Dashed line indicates in vivo relevant inhibition (eg, concentration that causes
$95% of b5i and ;50% of b5c inhibition similar to maximal tolerated dose in vivo18). (D) Clinically relevant concentrations of bortezomib or carfilzomib (n 5 2-3) have cytotoxicity
similar to that of ONX-0914. Dashed lines indicate clinically relevant doses. Except for KMS-11 (n 5 5), bortezomib data are from Figure 1 of Shabaneh et al.25 (E) IFN-g treatment
increases the sensitivity of MM cells to ONX-0914, but not to carfilzomib. Cells were treated with IFN-g for 5 days and then treated with ONX-0914 (upper left and bottom right) or
carfilzomib (bottom left) as in panel C. Upper right panel shows increase in b5i activity after 4 days as measured by BODIPY-NC-005-VS (n 5 2-3). Sp., specific.
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Figure 3. Addition of LU-102 sensitizes cells to in vivo relevant concentrations of ONX-0914. (A) Effect of 48-hour treatment with LU-102 on viability
MM cells as determined by Alamar Blue (n 5 2-4). (B) Inhibition of proteasome in MM1.S cells after 2-hour treatment as determined by the Proteasome-Glo
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not of b5i (PSMB8) and other immunoproteasome subunits.33
We conclude that b5c-dependent recovery of proteasome activity
can desensitize MM cells to b5i inhibitors, suggesting that an agent
that blocks recovery should be able to increase the efficacy of
immunoproteasome inhibitors.
LU-102 sensitizes cells to clinically relevant
concentrations of ONX-0914
We have shown that LU-102, the b2c and b2i inhibitor, dramatically
sensitizes MM cells to bortezomib and carfilzomib,11,12 and that
the mechanism of such sensitization involves inhibition of the Nrf1-
dependent recovery of proteasome activity.10 On the basis of this
phenomenon, we next tested whether LU-102 sensitizes cells to
ONX-0914. When used as a single agent, LU-102 did not cause
cell death at b2c/b2i-specific concentrations (Figure 3A-B), except
in the H929 cells that are highly sensitive to all proteasome
inhibitors. However, subtoxic b2-specifc concentrations of LU-102
dramatically sensitized MM cell lines to ONX-0914 (Figure 3C-D;
supplemental Figure 1A), decreasing the half maximal inhibitory
concentration by threefold to eightfold (Figure 3E) and reducing
viability of all cell lines treated for 1 hour with the pharmacologically
relevant 0.9 mMONX-0914 (Figure 3F). LU-102–induced decrease
in viability was similar in magnitude to the reduction seen in
carfilzomib-treated cells (supplemental Figure 1). The cells treated
with IFN-g were especially sensitive to the combined treatments.
Importantly, LU-102 synergized with ONX-0914 in inducing death
of CD1381 cells from MM patients (Figure 3G). As expected,
LU-102 blocked the recovery of b5 activity after treatment with
either carfilzomib or ONX-0914 (Figure 3H). Thus, LU-102 is a
potent sensitizer of MM cells to ONX-0914.
Addition of ONX-0914 to FDA-approved inhibitors
overcomes resistance
Our previous data indicate that inhibition of the b5i site is most
effective when b5c sites are also partially inhibited. These
conditions are achieved by combining ONX-0914 with lower
subtoxic doses of carfilzomib or bortezomib. Because such
combinations can be introduced into clinical trials more rapidly
than LU-102, we combined ONX-0914 and the FDA-approved
proteasome inhibitors. ONX-0914 synergized with bortezomib,
carfilzomib, and ixazomib in MM1.S (Figure 4A) and RPMI-8226
(Figure 4B) cell lines.
We decided to determine whether this synergistic interaction can
be recapitulated in an orthotopic murine model of MM, in which MM
cells form tumors in bone marrow if they are injected via the tail vein
into irradiated immunodeficient mice.30 Bortezomib was chosen over
carfilzomib for this study because initial clinical trials are performed in
heavily pretreated patients, and phase 1 trial candidates are more
likely to be refractory to bortezomib than to carfilzomib. The onset of
paraplegia and the presence of immunoglobulin G l-light chain
levels in the serum were used as readouts for tumor growth.
Bortezomib treatment alone slightly but significantly increased the
overall survival in the experimental model compared with vehicle-
injected mice (Figure 4C). Although ONX-0914 treatment alone
did not increase survival, the combination of ONX-0914 and
bortezomib delayed the appearance of l-light chains in blood
and significantly increased the overall survival compared with the
vehicle group and the bortezomib-only group without obvious
signs of additional toxicity. Thus, ONX-0914 synergizes with
bortezomib in vivo.
Discussion
Our data provide a strong rationale for the use of a combination
therapy that includes immunoproteasomes and b2 inhibitors. ONX-
0914 is the precursor of KZR-616, which is currently being
developed for the treatment of autoimmune disorders and for
which a phase 1 trial in healthy volunteers has been successfully
completed.23 Although KZR-616 was not available to us, the active
site inhibition profile for it resembles that for ONX-0914, which has
been used in our work (Christopher Kirk, Kezar Life Sciences, oral
communication, 18 April 2017). Because b2 inhibitors are at the
early stages of preclinical development, an increase in overall survival
of mice treated with bortezomib and ONX-0914 suggests that
combinations of KZ-616 with one of the FDA-approved proteasome
inhibitors will yield the fastest route to the clinic.
To successfully translate these findings in the clinic, upregulation of
constitutive proteasomes in response to b5i inhibition, which we
detected independently (Figure 2) and which 2 other laboratories
also detected,17,34 must be addressed. We suggest that immuno-
proteasome inhibitors should be combined with agents that, like
LU-102, block the recovery of activity. Expression of constitutive
proteasomes is upregulated by Nrf1. Nrf1 activation involves
ubiquitin, VCP ATPase, and proteolytic activation by DDI2, an
aspartic protease similar to HIV protease.31,32,35-37 Inhibitors of
VCP138 and of E1 ubiquitin-activating enzyme39 are undergoing
clinical trials, and it should not be difficult to develop DDI2
inhibitors.
The content of immunoproteasomes varies among patients with
MM,5 and we clearly show that increased immunoproteasome
expression selectively sensitizes cells to immunoproteasome inhibi-
tors. Therefore, all clinical trials of immunoproteasome inhibitors
in myeloma or hematologic malignancies should involve patient
stratification. In addition to the enzyme-linked immunosorbent
assay–based ProCISE assay developed by ONYX,6 we have
developed several subunit-specific assays26,40 that can be adopted
for clinical use.
Figure 3. (continued) assay (n 5 3) (Promega). (C) MM1.S cells were treated with ONX-0914 for 1 hour, and then treated with 1 mM LU-102 for 47 hours (n 5 3).
(D) MM1.S cells were cotreated for 4 hours with ONX-0914 and 3 mM LU-102 (n 5 2). (E) Cells were treated by ONX-0914, followed by LU-102 (250 nM in
H929 and MM1.R, 1 mM in all others) for 47 hours (n 5 2-6), and half maximal inhibitory concentrations of MM cells was determined form dose-response curves
(supplemental Figure 1). (F) Viability of cells treated with 900 nM ONX-0914 in experiment shown in panel E. Numbers are combination indexes (CIs). (G) Primary
cells isolated from plural effusions of bortezomib-refractory patients were treated with 0.9 mM ONX-0914 for 4 hours with or without 2 mM LU-102, and viability of
CD1381 cells was determined by flow cytometry at 48 hours using PE Mouse Anti-Human CD138 and Zombie Aqua Fixable Viability antibodies. (H) LU-102 blocks
the recovery of b5i/b5c activity over time after 1-hour treatment. Total b5 activity was measured with Proteasome-Glo in RPMI-8226 cells, either immediately after
1-hour treatment with 1 mM ONX-0914 or 100 nM carfilzomib or after a 17-hour recovery in the presence or absence of 1 mM LU-102 (n 5 2). Pt., patient.
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In summary, this work provides a strong rationale for the
development of immunoproteasome inhibitors in the treatment
of patients with MM and also raises the possibility that these
agents will be of therapeutic value for the treatment of other
hematologic malignancies that also express high levels of
immunoproteasomes.41,42
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Figure 4. ONX-0914 is synergistic with FDA-approved inhibitors. (A-B) ONX-0914 is synergistic with bortezomib (Btz), carfilzomib (Cfz), and ixazomib (Ixa) in MM1.S (A) and
RPMI-8226 (B) cells (n 5 2). Numbers on the graph are CIs. (C) ONX-0914 and bortezomib have synergistic activity in orthotopic mouse model of MM. NSG mice (6 per group) were
injected intravenously with MM1.S cells and then treated as shown. Weight at euthanasia is not included on the right graph because animals lose weight as a result of disease
progression. Error bars indicate standard error of the mean. Bottom: 1 mL of serum samples was assayed for human Igl by western blot. The latest sample was taken at euthanasia.
*P , .05 when compared with vehicle group; **P , .005 when compared with vehicle group; ##P , .005 when compared with bortezomib only group. PI, proteasome inhibitor.
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